Isis' financing vehicle supports CV/metabolic development
In a deal expected to last four years, antisense drug developer Isis Pharmaceuticals has licensed intellectual property related to its cholesterol candidate ISIS301012 and two diabetes programs to Symphony GenIsis, an off-balance sheet entity that was formed by a $75mm investment from private equity company Symphony Capital and other co-investors.
- Antisense, Oligonucleotides
- Large Molecule
- Special-Purpose Financing Vehicle
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com